← All trials
NCT05027815
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 11, 2021
- Primary completion
- Aug 31, 2022
- Completion date
- Nov 30, 2022
- First posted
- Aug 30, 2021
- Last posted
- Oct 19, 2021
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San FranciscoLead sponsor
- Immune Tolerance NetworkCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Yale UniversityStudy chair
- University of California, San FranciscoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.